2020
DOI: 10.1007/s11239-020-02154-z
|View full text |Cite|
|
Sign up to set email alerts
|

Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products

Abstract: To analyze the efficacy and safety of activated prothrombin complex concentrates (aPCC) and four-factor prothrombin complex concentrates (4F-PCC) to prevent hematoma expansion in patients taking apixaban or rivaroxaban with intracranial hemorrhage (ICH). In this multicenter, retrospective study, sixty-seven ICH patients who received aPCC or 4F-PCC for known use of apixaban or rivaroxaban between February 2014 and September 2018 were included. The primary outcome was the percentage of patients who achieved exce… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
22
1

Year Published

2021
2021
2023
2023

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 30 publications
(24 citation statements)
references
References 22 publications
0
22
1
Order By: Relevance
“…and factor Xa inhibitors. [169][170][171] RRT may reduce dabigatran concentration. 177 In patients on heparin, protamine reverses the anticoagulant effect.…”
Section: Cor Loe Recommendationsmentioning
confidence: 99%
“…and factor Xa inhibitors. [169][170][171] RRT may reduce dabigatran concentration. 177 In patients on heparin, protamine reverses the anticoagulant effect.…”
Section: Cor Loe Recommendationsmentioning
confidence: 99%
“…The level of evidence supporting these 4F-PCC dosing recommendations are generally acknowledged as low (based on studies assessing the correction of anticoagulant-induced laboratory abnormalities or punch biopsy studies) and the strength of recommendations deemed weak [31,33,35,37]. Multiple studies comparing the hemostatic effectiveness of lower (25 u/kg, < 30 u/kg, or < 35 u/kg) and higher (≥ 30 u/kg, ≥ 35 u/kg, or 50 u/kg) 4F-PCC doses have failed to show significant differences between dosing strategies [38][39][40]. Fourth, as this was not a randomized controlled trial, the risk of confounding bias exists [38].…”
Section: Study Strengths and Limitationsmentioning
confidence: 99%
“… The criteria for effective hemostasis used in Annexa‐4 are adjusted Sarode criteria and included in Appendix S2 38 …”
Section: Resultsmentioning
confidence: 99%